NCT00470301View on ClinicalTrials.gov

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Breast CancerMale Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
DRUG

tipifarnib

Given orally

DRUG

paclitaxel

Given IV

DRUG

doxorubicin

Given IV

DRUG

cyclophosphamide

Given IV

Trial Locations (7)

10029

Mount Sinai Medical Center, New York

10032

Columbia University Medical Center, New York

10065

Weill Medical College of Cornell University, New York

10461

Albert Einstein College of Medicine, The Bronx

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

77030

M D Anderson Cancer Center, Houston

10467-2490

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00470301 - Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | Biotech Hunter | Biotech Hunter